These findings validate FANCG- and BRCA1-PLK1 synthetic lethal interactions in the setting of AML and identify novel synthetic lethal interactions between PLK1 and two additional FA pathway members (FANCE and FANCD2). The gene discussed is BRCA1; the disease is acute myeloid leukemia.